You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

B cell line

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Diffuse Large B-cell Lymphoma Trial in Changchun (Mitoxantrone HCl liposome injection, RiTUXimab Injection, Cyclophosphamid)

Not yet recruiting
  • Diffuse Large B-cell Lymphoma
  • Mitoxantrone hydrochloride liposome injection
  • +4 more
  • Changchun, Jilin, China
    The First Bethune Hospital of Jilin University
Aug 15, 2023

Diffuse Large B Cell Lymphoma Trial (Epcoritamab, Lenalidomide)

Not yet recruiting
  • Diffuse Large B Cell Lymphoma
  • (no location specified)
Jan 20, 2023

DLBCL, Not Otherwise Specified Trial in Chongqing (selinexor)

Recruiting
  • Diffuse Large B-Cell Lymphoma, Not Otherwise Specified
  • Chongqing, Chongqing, China
    Chongqing University Cancer Hospital
Mar 27, 2023

Lymphoma, Large B-Cell, Diffuse, Follicular Lymphoma Grade 3B, High-grade B-cell Lymphoma Trial in China (Relmacabtagene

Not yet recruiting
  • Lymphoma, Large B-Cell, Diffuse
  • +3 more
  • Relmacabtagene Autoleucel
  • +2 more
  • Guangzhou, Guangdong, China
  • +12 more
Oct 24, 2023

B-cell Lymphoma Trial in Beijing (Relmacabtagene Autoleucel, Fludarabine, Cyclophosphamide)

Not yet recruiting
  • B-cell Lymphoma
  • Relmacabtagene Autoleucel
  • +2 more
  • Beijing, Beijing, China
  • +1 more
Oct 19, 2022

Non-small Cell Lung Adenocarcinoma, Squamous Cell Carcinoma of Lung Trial in Guangzhou (SI-B001, Docetaxel)

Not yet recruiting
  • Non-small Cell Lung Adenocarcinoma
  • Squamous Cell Carcinoma of Lung
  • Guangzhou, Guangdong, China
    Sun Yat-sen University Cancer Center
Jul 5, 2023

High-risk Large B-cell Lymphoma (LBCL) Trial (Axicabtagene Ciloleucel, Cyclophosphamide, Fludarabine)

Not yet recruiting
  • High-risk Large B-cell Lymphoma (LBCL)
  • Axicabtagene Ciloleucel
  • +7 more
  • (no location specified)
Dec 13, 2022

OR Regimen Refractory Marginal Zone Lymphoma Trial (obrutinib, rituximab)

Not yet recruiting
  • OR Regimen Refractory Marginal Zone Lymphoma
  • obrutinib, rituximab
  • (no location specified)
Nov 12, 2023

Renal Cell Carcinoma Trial in Houston (Ipilimumab, Nivolumab, Ciforadenant)

Not yet recruiting
  • Renal Cell Carcinoma
  • Houston, Texas
    M D Anderson Cancer Center
Aug 11, 2022

Diffuse Large B-cell Lymphoma Trial in Toulouse (Patient with histologically confirmed diffuse large B-cell lymphoma with a

Recruiting
  • Diffuse Large B-cell Lymphoma
  • Patient with histologically confirmed diffuse large B-cell lymphoma with a planned first line treatment by R-CHOP.
  • Toulouse, France
    Institut Universitaire du Cancer Toulouse - Oncopole
Mar 28, 2022

Non-Hodgkin Lymphoma, Large B-cell Lymphoma Trial in Palo Alto (Axicabtagene Ciloleucel)

Not yet recruiting
  • Non-Hodgkin Lymphoma
  • Large B-cell Lymphoma
  • Axicabtagene Ciloleucel
  • Palo Alto, California
    Stanford University
Mar 20, 2023

EBV-associated Lymphomas Trial ((Autologous monocyte-derived DCs pulsed with allogeneic EBV-transformed B-lymphoblastoid cell

Not yet recruiting
  • EBV-associated Lymphomas
  • (Autologous monocyte-derived DCs pulsed with allogeneic EBV-transformed B-lymphoblastoid cell line lysate
  • (no location specified)
May 31, 2023

Diffuse Large B Cell Lymphoma Trial in France (ONCOLAXY Follow-up)

Not yet recruiting
  • Diffuse Large B Cell Lymphoma
  • ONCOLAXY Follow-up
  • Bordeaux, France
  • +4 more
Mar 25, 2022

Extensive Stage Lung Small Cell Carcinoma, Metastatic Lung Small Cell Carcinoma, Recurrent Lung Small Cell Carcinoma Trial in

Recruiting
  • Extensive Stage Lung Small Cell Carcinoma
  • +5 more
  • Indianapolis, Indiana
  • +2 more
Oct 26, 2022

Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Chronic Lymphocytic, Small-Cell Lymphoma Trial (Nemtabrutinib, Venetoclax,

Not yet recruiting
  • Leukemia, Lymphocytic, Chronic, B-Cell
  • +5 more
  • (no location specified)
Jul 21, 2023

CAR Trial in Hefei (CD19/CD20 CAR-T cell infusion)

Recruiting
  • CAR
  • CD19/CD20 CAR-T cell infusion
  • Hefei, Anhui, China
    Anhui Provincial Hospital
Mar 4, 2021

Metastatic Urothelial Carcinoma, Urothelial Tumors Trial (Coformulated favezelimab/pembrolizumab, Coformulated

Not yet recruiting
  • Metastatic Urothelial Carcinoma
  • Urothelial Neoplasms
  • Coformulated favezelimab/pembrolizumab
  • +3 more
  • (no location specified)
Apr 26, 2023

Non-Small-Cell Lung Carcinoma Trial (biological, drug, dietary supplement)

Active, not recruiting
Has Results
  • Non-Small-Cell Lung Carcinoma
  • Pembrolizumab 200 mg
  • +7 more
  • (no location specified)
Aug 16, 2022

Non Hodgkin Lymphoma, Diffuse Large B Cell Lymphoma Trial in Nanjing, Nanjin (Zanubrutinib, Lenalidomide, Rituximab)

Recruiting
  • Non Hodgkin Lymphoma
  • Diffuse Large B Cell Lymphoma
  • Nanjing, Jiangsu, China
  • +1 more
Mar 9, 2022

Follicular Lymphoma, Marginal Zone Lymphoma, B-cell Lymphoma Trial in New Haven, New Brunswick, Providence (Mosunetuzumab,

Recruiting
  • Follicular Lymphoma
  • +2 more
  • New Haven, Connecticut
  • +2 more
Jul 14, 2022

DLBCL Trial (Sintilimab, Rituximab)

Not yet recruiting
  • Diffuse Large B-Cell Lymphoma
  • (no location specified)
Mar 6, 2022

Unfit CLL Included in GIMEMA LLC1114 Trial Who Discontinued

Not yet recruiting
  • Chronic Lymphocytic Leukemia
  • Observation
  • (no location specified)
Oct 12, 2023

NSCLC Stage III Trial in Worldwide (Nivolumab)

Completed
Has Results
  • Non-small Cell Lung Cancer Stage III
  • Leuven, Belgium
  • +10 more
Aug 23, 2022

Leukemia, Chronic Lymphatic Trial in Stuttgart, Tuebingen (Peptide Vaccine, Imiquimod)

Completed
  • Leukemia, Chronic Lymphatic
  • Stuttgart, Baden-Wuerttemberg, Germany
  • +4 more
Nov 24, 2022

NSCLC Trial in Canada (Osimertinib First-Line, Platinum + Pemetrexed Chemotherapy Second-Line, Osimertinib Third-Line)

Recruiting
  • Non-Small Cell Lung Cancer
  • Osimertinib First-Line
  • +2 more
  • Vancouver, British Columbia, Canada
  • +9 more
Jun 21, 2022